Hideaki Bando, Kyoko Yamaguchi, Seiichiro Mitani, Kentaro Sawada, Saori Mishima, Keigo Komine, Yoshinaga Okugawa, Waki Hosoda, Hiromichi Ebi. Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer science. 2024. 115. 3. 1014-1021
Xianning Lai, Sarah Kit Leng Lui, Hiu Yan Lam, Yuta Adachi, Wen Jing Sim, Natali Vasilevski, Nicola J Armstrong, Stephanie Claire Bridgeman, Nathan Michael Main, Tuan Zea Tan, et al. SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition. NPJ precision oncology. 2023. 7. 1. 136-136
Junichi Matsubara, Kumi Mukai, Tomohiro Kondo, Masahiro Yoshioka, Hidenori Kage, Katsutoshi Oda, Ryo Kudo, Sadakatsu Ikeda, Hiromichi Ebi, Kei Muro, et al. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities. JAMA network open. 2023. 6. 7. e2323336
Yuta Adachi, Ryo Kimura, Kentaro Hirade, Shogo Yanase, Yuki Nishioka, Natsumi Kasuga, Rui Yamaguchi, Hiromichi Ebi. Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. Nature cancer. 2023. 4. 6. 829-843
Hiromichi Ebi. Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor Microenvironment. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023. 18. 4. 399-401
